ImmuPharma plc (LON:IMM – Get Free Report)’s share price was up 14.7% on Friday . The company traded as high as GBX 3.50 ($0.04) and last traded at GBX 3.01 ($0.04). Approximately 2,001,006 shares changed hands during trading, a decline of 91% from the average daily volume of 22,726,049 shares. The stock had previously closed at GBX 2.63 ($0.03).
ImmuPharma Stock Performance
The firm has a market cap of £12.53 million, a P/E ratio of -301.00 and a beta of 1.53. The firm has a fifty day moving average of GBX 1.56 and a 200-day moving average of GBX 1.68.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Stories
- Five stocks we like better than ImmuPharma
- What Are Some of the Best Large-Cap Stocks to Buy?
- Cerence AI: One-Hit Wonder or Long-Term Winner After NVIDIA Pact?
- How Investors Can Find the Best Cheap Dividend Stocks
- UnitedHealth Group Pulls Back Into Another Healthy Opportunity
- How to Use the MarketBeat Dividend Calculator
- Micron Technology: Riding the AI Wave to Long-Term Growth
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
